19.09.2024 14:21:35
|
AIM Reports Positive Preliminary Data From Phase 1b/2 Study Of Ampligen, Imfinzi As Combination
(RTTNews) - AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of late-stage pancreatic cancer. The combination therapy was generally well-tolerated with no severe adverse events or dose-limiting toxicities. The first cohort has now reached the pre-determined 6-month stability assessment timepoint and two of the three subjects remain stable.
AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The company's lead product is a first-in-class investigational drug called Ampligen.
For More Such Health News, visit rttnews.com.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Hemispherx Biopharma Inc Registered Shsmehr Nachrichten
14.11.24 |
Ausblick: Hemispherx Biopharma verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Hemispherx Biopharma Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 71,50 | 2,14% |
|
Hemispherx Biopharma Inc Registered Shs | 0,13 | 7,50% |
|